ReviewThe protein journal2026
G6PD: An Old Player with Multiple Emerging Roles from Cancer Progression to Metastasis and Chemoresistance.
Review in The protein journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of pentose phosphate pathway (PPP). It provides essential NADPH for redox balance and ribose-5-phosphate for nucleotide synthesis. Cancer and metastasis are linked to G6PD dysregulation, which allows tumors to progress and tolerate chemotherapy. The molecular mechanisms that hyperactivate G6PD to encourage proliferation, epithelial-mesenchymal transition (EMT), and metastatic niche adaptation are described in this work. Additionally, this review details new post-translational, protein-interaction, and epitranscriptomic control of G6PD and highlights its developing role in cancer. The function of G6PD in nucleotide synthesis and antioxidant defense is being investigated to see if it can lead to resistance to conventional and customized treatments. Lastly, we look at the predictive and therapeutic potential of G6PD. We also discuss new inhibitors and sensible combination strategies that have the potential to transform cancer therapy.
Identifiers
42426331What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.